ANR granted the TROY program

By 7 juillet 2016News

NETRIS Pharma announces that ANR (Agence Nationale de la Recherche) granted the translational RHU TROY program aiming at Targeting dependence Receptors (DRs) in Oncology and hematologY. This program aims at deciphering the role of DRs in the specific context of onco-hematology and at leading 2 proof-of-concept clinical trials with new innovative monoclonal antibody therapies targeting 2 different DRs ligands. The consortium in charge of developing this program involves: (1) DIPOHL (Département pour l’Innovation et le Progrès en Onco-Hématologie à Lyon) as coordinator, (2) CRCL (Centre de Recherche en Cancérologie de Lyon) as an academic partner and (3) NETRIS Pharma as an industrial partner. Overall, the TROY program will be supported by a 9M€ ANR grant. For further details, see: Life film now